These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-003236-59 Double Blind Placebo Controlled Clinical Investigation into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients with Severe Pulmonary Arterial Hypertension Double Blind Placebo... 2011-07-20 due-trials
Reported results 2006-000800-17 A 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Re... 2008-09-29 due-trials
Reported results 2006-000801-50 A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial H... 2011-04-29 due-trials
Reported results 2006-000804-18 An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension 2020-02-12 due-trials
Reported results 2008-005018-39 DISTOL-1:Digital Ischaemic Lesions in Scleroderma treated with Oral Treprostinil Diethanolamine: A randomized, double-blind, placebo controlled, multicenter study 2011-02-24 due-trials
Reported results 2008-006978-15 DISTOL-EXT:Digital Ischaemic Lesions in Scleroderma treated with Oral Treprostinil Diethanolamine: An open-label multicenter extension study 2011-09-13 due-trials
Reported results 2009-009366-13 A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypert... 2012-02-07 due-trials
Reported results 2011-004631-31 A 16 Week, Open Label, Multi-Centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin® Therapy in Subjects with Pulmon... 2014-03-20 due-trials
Reported results 2012-000097-26 A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral M... 2018-09-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-000098-21 An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Studio di estensione in aperto su UT-15C in soggetti con ipert... 2021-08-12 bad-data
Listed as ongoing, but also has a completion date 2014-003042-27 An Open-Label Extension Study of APD811-003 in Patients with Pulmonary Arterial Hypertension Az APD811-003 vizsgálat nyílt kiterjesztett vizsgálata pulmonális artériás hipertóniában szenvedő betege... 2021-03-29 bad-data
Reported results 2017-000758-20 A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer 2020-03-27 due-trials
Ongoing 2018-001187-33 A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients not-yet-due
Ongoing 2018-001189-40 A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION not-yet-due
Listed as ongoing, but also has a completion date 2019-003309-88 A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Healt... 2023-04-12 bad-data
Ongoing 2021-005881-17 A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2) not-yet-due
Trial is outside EEC, and reported results 2023-001028-40 Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study bad-data